Immunotoxins and methods of inducing immune tolerance
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsDavid M. Neville, Jerry T. Thompson
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsDavid M. Neville, Jerry T. Thompson
Estimating the term…
Provided are novel DT- and ETA-based immunotoxins and a method of treating an immune system disorder not involving T cell proliferation, comprising administering to the animal an immunotoxin comprising a mutant diphtheria toxin moiety linked to an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the disorder is treated. Thus, the present method can treat graft-versus-host disease. Also provided is a method of inhibiting a rejection response by inducing immune tolerance in a recipient to a foreign mammalian donor tissue or cells, comprising the steps of: a) exposing the recipient to an immunotoxin so as to reduce the recipients' peripheral blood T-cell lymphocyte population by at least 80%, wherein the immunotoxin is anti-CD3 antibody linked to a diphtheria protein toxin, wherein the protein has a binding site mutation; and b) transplanting the donor cells into the recipient, whereby a rejection response by the recipient to the donor organ cell is inhibited, and the host is tolerized to the donor cell.
An anti-T cell immunotoxin fusion protein comprising a diphtheria toxin moiety and a targeting moiety, wherein the sequence from the amino terminus from left to right is toxin moiety, VL,L,VH,L,VL,L,VH, wherein the toxin moiety comprises a truncation mutation, L is a (G4S)3 (SEQ ID NO:16) linker, and VL and VH are the variable light and heavy domains of the anti-CD3 antibody UCHT1.
Dependencies are inferred from the claim text.